Literature DB >> 10893438

Apicidin, an inhibitor of histone deacetylase, prevents H-ras-induced invasive phenotype.

M S Kim1, M W Son, W B Kim, Y In Park, A Moon.   

Abstract

Cancer metastasis represents the most important cause of cancer death and agents that may inhibit tumor cell invasion have been extensively pursued. In the present study, we have examined the anti-invasive effect of apicidin [cyclo(N-O-methyl-L-tryptophanyl-L-isoleucinyl-D-pipecolinyl -L-2-amin o-8-oxodecanoyl)], a fungal metabolite that was identified as an antiprotozoal agent known to inhibit parasite histone deacetylase (HDAC). We show that apicidin significantly inhibits H-ras-induced invasive phenotype of MCF10A human breast epithelial cells in parallel with a specific downregulation of matrix metalloproteinase (MMP)-2, but not MMP-9. We also show that apicidin induces a morphological reversal and growth inhibition of H-ras MCF10A cells similar to that induced by other HDAC inhibitors. Taken in conjunction with the fact that uncontrolled ras activation is probably the most common genetic defect in human cancer cells, our data showing the anti-invasive and detransforming activities of apicidin in H-ras-transformed MCF10A cells may suggest a potential use of HDAC inhibitors for treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10893438     DOI: 10.1016/s0304-3835(00)00465-1

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  9 in total

1.  Apicidin-resistant HA22T hepatocellular carcinoma cells massively promote pro-survival capability via IGF-IR/PI3K/Akt signaling pathway activation.

Authors:  Hsi-Hsien Hsu; Li-Hao Cheng; Tsung-Jung Ho; Wei-Wen Kuo; Yueh-Min Lin; Ming-Cheng Chen; Nien-Hung Lee; Fuu-Jen Tsai; Kun-Hsi Tsai; Chih-Yang Huang
Journal:  Tumour Biol       Date:  2013-08-30

2.  Treponema denticola increases MMP-2 expression and activation in the periodontium via reversible DNA and histone modifications.

Authors:  Islam M Ateia; Pimchanok Sutthiboonyapan; Pachiyappan Kamarajan; Taocong Jin; Valentina Godovikova; Yvonne L Kapila; J Christopher Fenno
Journal:  Cell Microbiol       Date:  2018-01-08       Impact factor: 3.715

3.  Phosphorylation of cofilin-1 by ERK confers HDAC inhibitor resistance in hepatocellular carcinoma cells via decreased ROS-mediated mitochondria injury.

Authors:  P-H Liao; H-H Hsu; T-S Chen; M-C Chen; C-H Day; C-C Tu; Y-M Lin; F-J Tsai; W-W Kuo; C-Y Huang
Journal:  Oncogene       Date:  2016-10-17       Impact factor: 9.867

4.  Histone deacetylase inhibitors enhance Candida albicans sensitivity to azoles and related antifungals: correlation with reduction in CDR and ERG upregulation.

Authors:  W Lamar Smith; Thomas D Edlind
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

Review 5.  Histone deacetylases (HDACs): characterization of the classical HDAC family.

Authors:  Annemieke J M de Ruijter; Albert H van Gennip; Huib N Caron; Stephan Kemp; André B P van Kuilenburg
Journal:  Biochem J       Date:  2003-03-15       Impact factor: 3.857

6.  Alterations in metastatic properties of hepatocellular carcinoma cell following H-ras oncogene transfection.

Authors:  Q Wang; Z Y Lin; X L Feng
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

7.  Regulation of immune responses by histone deacetylase inhibitors.

Authors:  Paul V Licciardi; Tom C Karagiannis
Journal:  ISRN Hematol       Date:  2012-03-18

8.  Histone deacetylase inhibitors: a new mode for inhibition of cholesterol metabolism.

Authors:  Sridar V Chittur; Niquiche Sangster-Guity; Paulette J McCormick
Journal:  BMC Genomics       Date:  2008-10-29       Impact factor: 3.969

9.  A New Histone Deacetylase Inhibitor, MHY219, Inhibits the Migration of Human Prostate Cancer Cells via HDAC1.

Authors:  Umasankar De; Soma Kundu; Nabanita Patra; Mee Young Ahn; Ji Hae Ahn; Ji Yeon Son; Jung Hyun Yoon; Hyung Ryoung Moon; Byung Mu Lee; Hyung Sik Kim
Journal:  Biomol Ther (Seoul)       Date:  2015-09-01       Impact factor: 4.634

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.